Order Article Reprints

Rachiglio AM, Fenizia F, Piccirillo MC, Galetta D, Crinò L, Vincenzi B, Barletta E, Pinto C, Ferraù F, Lambiase M, et al. The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers. 2019; 11(3):341. https://doi.org/10.3390/cancers11030341

Rachiglio, Anna Maria, Francesca Fenizia, Maria Carmela Piccirillo, Domenico Galetta, Lucio Crinò, Bruno Vincenzi, Emiddio Barletta, Carmine Pinto, Francesco Ferraù, Matilde Lambiase, and et al. 2019. "The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients" Cancers 11, no. 3: 341. https://doi.org/10.3390/cancers11030341

Rachiglio, A. M., Fenizia, F., Piccirillo, M. C., Galetta, D., Crinò, L., Vincenzi, B., Barletta, E., Pinto, C., Ferraù, F., Lambiase, M., Montanino, A., Roma, C., Ludovini, V., Montagna, E. S., De Luca, A., Rocco, G., Botti, G., Perrone, F., Morabito, A., & Normanno, N. (2019). The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 11(3), 341. https://doi.org/10.3390/cancers11030341